Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
You may also be interested in...
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.